-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Oncosec Healthcare announced today that its main candidate drug, TAVO™, is co-treated with PD-1 inhibitor KEYTRUDA ® ,pmbrolizumab, producing a total remission rate (ORR) of 41% and a total remission rate of 36%TAVO ™ is a gene therapy that delivers DNA-based leukin 12 (IL-12), a naturally occurring protein with immune stimulation, in tumorsTAVO ™ uses electroperforation technology to partially express IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors"Combining pembrolizumab with TAVO electroperforation can improve the poor response of late stage patients to immunocheckpoint inhibitor single-drug therapy," said Adil Daud, clinical professor at the University of California, San Francisco (UCSF) at the
By using electroperforated local delivery of TAVO, we are able to avoid many of the toxicity associated with systemic IL-12 administration while still obtaining clinical responses."in the trial, 9 of the 22 assessable patients observed remission, with an objective remission rate of 41%Thirty-six percent of patients experienced complete remissionThe median progression survival period was 5.6 months, and the median follow-up was 19.6 months laterLevel 3 or higher adverse events include pain, chills, and cellular itisis
